Manchester Metropolitan University's Research Repository

CD105 inhibits transforming growth factor-beta-Smad3 signalling

Guo, Baoqiang and Slevin, Mark and Li, Chenggang and Parameshwar, Sudeep and Liu, Donghui and Kumar, Patricia and Bernabeu, Carmelo and Kumar, Shant (2004) CD105 inhibits transforming growth factor-beta-Smad3 signalling. ISSN 0250-7005

Full text not available from this repository.


CD105 (endoglin) is an important component of the transforming growth factor-beta (TGF-beta) receptor complex and is highly expressed in endothelial cells in tissues undergoing angiogenesis such as healing wounds, infarcts and in a wide range of tumours. In an attempt to understand the molecular mechanism by which CD105 exerts its effects on angiogenesis by modulating TGF-beta1 signalling, in this preliminary communication, CD105 transfected rat myoblasts were utilized as an in vitro model. Overexpression of CD105 in these transfectants antagonised TGF-beta1-mediated inhibition of cell proliferation and reduced TGF-beta1-mediated p3TP-Lux (PAI-1 promoter) luciferase activity. It also reduced (CAGA)12-Luc luciferase activity in response to TGF-beta1. The CAGA sequence is specific for Smad3/4 binding, implying that CD105 is involved in inhibition of TGF-beta1/Smad3 signalling. Furthermore, CD105 overexpression reduced serine phosphorylation of Smad3 and inhibited subsequent nuclear translocation of Smad3. CD105 resulted in high phosphorylation of JNK1, which is able to activate c-Jun. c-Jun is known to inhibit Smad3 transcriptional activity on CAGA sites, suggesting that CD105 may also inhibit Smad3 signalling through JNK1.

Impact and Reach


Activity Overview

Additional statistics for this dataset are available via IRStats2.

Actions (login required)

View Item View Item